Lannett Company Inc (LCI, Financial) filed Quarterly Report for the period ended 2010-09-30.
Lannett Company Inc has a market cap of $153.2 million; its shares were traded at around $6.07 with a P/E ratio of 20.2 and P/S ratio of 1.2. LCI is in the portfolios of Jim Simons of Renaissance Technologies LLC, Chuck Royce of Royce& Associates.
Concentration of Market and Credit Risk - Five of the Companys products, defined as generics containing the same active ingredient or combination of ingredients, accounted for approximately 41%, 13%, 10%, 4% and 3%, respectively of net sales for the three months ended September 30, 2010. Those same products accounted for 41%, 15%, 8%, 3% and 5% respectively, of net sales for the three months ended September 30, 2009.
Four of the Companys customers accounted for 23%, 13%, 9%, and 9%, respectively, of net sales for the three months ended September 30, 2010, and 25%, 12%, 8%, and 8%, respectively, of net sales for the three months ended September 30, 2009. At September 30, 2010, four customers accounted for 64% of the Companys accounts receivable balances. At June 30, 2010, four customers accounted for 69% of the Companys accounts receivable balances.
Read the The complete Report
Lannett Company Inc has a market cap of $153.2 million; its shares were traded at around $6.07 with a P/E ratio of 20.2 and P/S ratio of 1.2. LCI is in the portfolios of Jim Simons of Renaissance Technologies LLC, Chuck Royce of Royce& Associates.
Highlight of Business Operations:
On April 10, 2007, the Company entered into a Stock Purchase Agreement to acquire Cody by purchasing all of the remaining shares of common stock of Cody. The consideration for the April 10, 2007 acquisition was approximately $4,438,000, which represented the fair value of the tangible net assets acquired. The agreement also required Lannett to issue to the sellers up to 120,000 shares of unregistered common stock of the Company contingent upon the receipt of a license from a regulatory agency. This license was subsequently received in July 2008 and triggered the payment of 105,000 shares (87.5% of the 120,000 shares to be issued as the Company already owned 12.5% of Cody) of Lannett stock to the former owners of Cody Labs, which was completed in October 2008. Therefore, the Company recorded an intangible asset related to the acquisition of a drug import license in the original amount of $581,175 and recorded a corresponding deferred tax liability of approximately $150,700 due to the non-deductibility of the amortization for tax purposes. The Company has assigned a 15 year life to this intangible asset based on average life cycles of Lannett products.Concentration of Market and Credit Risk - Five of the Companys products, defined as generics containing the same active ingredient or combination of ingredients, accounted for approximately 41%, 13%, 10%, 4% and 3%, respectively of net sales for the three months ended September 30, 2010. Those same products accounted for 41%, 15%, 8%, 3% and 5% respectively, of net sales for the three months ended September 30, 2009.
Four of the Companys customers accounted for 23%, 13%, 9%, and 9%, respectively, of net sales for the three months ended September 30, 2010, and 25%, 12%, 8%, and 8%, respectively, of net sales for the three months ended September 30, 2009. At September 30, 2010, four customers accounted for 64% of the Companys accounts receivable balances. At June 30, 2010, four customers accounted for 69% of the Companys accounts receivable balances.
Read the The complete Report
